Phase II trials and stem cell therapies
There are more than a dozen or so treatments in Phase II trials, including agonists for PPAR and farnesoid X receptors, such as Enanta’s EDP 305.
Enanta plans to start a further Phase III trial ARGON-2 in NASH in early Q2 2020 and start a Phase I study of EDP 297 as a follow up FXR agonist.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest